X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2763) 2763
Publication (175) 175
Newsletter (85) 85
Book Review (56) 56
Newspaper Article (14) 14
Magazine Article (9) 9
Book Chapter (6) 6
Conference Proceeding (6) 6
Trade Publication Article (2) 2
Data Set (1) 1
Dissertation (1) 1
Paper (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
exenatide (2217) 2217
index medicus (1517) 1517
humans (1476) 1476
type 2 diabetes (1079) 1079
diabetes mellitus, type 2 - drug therapy (1039) 1039
endocrinology & metabolism (939) 939
male (893) 893
glucagon-like peptide-1 (873) 873
hypoglycemic agents - therapeutic use (779) 779
diabetes (775) 775
liraglutide (719) 719
glycemic control (692) 692
animals (674) 674
female (653) 653
insulin (564) 564
middle aged (516) 516
glucose (510) 510
metformin (485) 485
pharmacology & pharmacy (479) 479
peptides - therapeutic use (464) 464
hypoglycemic agents - administration & dosage (433) 433
venoms - therapeutic use (424) 424
glucagon (423) 423
peptides - pharmacology (383) 383
glp-1 (378) 378
peptides (361) 361
venoms - pharmacology (346) 346
hypoglycemic agents - adverse effects (340) 340
exenatide exendin-4 (336) 336
aged (334) 334
exendin-4 (333) 333
diabetes mellitus, type 2 - blood (328) 328
open-label (324) 324
adult (323) 323
care and treatment (320) 320
treatment outcome (320) 320
diabetes mellitus (319) 319
hypoglycemic agents (319) 319
peptides - administration & dosage (318) 318
glucagon-like peptide 1 - analogs & derivatives (308) 308
diabetes therapy (307) 307
glucagon-like peptide-1 receptor (305) 305
hypoglycemic agents - pharmacology (304) 304
research (304) 304
blood glucose - metabolism (294) 294
venoms - administration & dosage (289) 289
analysis (288) 288
medicine, general & internal (286) 286
internal medicine (281) 281
drug therapy (279) 279
obesity (277) 277
rats (277) 277
double-blind (276) 276
blood glucose - drug effects (275) 275
safety (268) 268
sitagliptin (264) 264
treated patients (262) 262
efficacy (255) 255
glucagon-like peptide 1 - therapeutic use (243) 243
mice (241) 241
insulin - metabolism (234) 234
type 2 diabetes mellitus (232) 232
risk factors (231) 231
receptors, glucagon - agonists (230) 230
type-2 diabetes-mellitus (229) 229
beta-cell function (222) 222
glucagon-like peptide 1 (215) 215
dextrose (207) 207
clinical trials (205) 205
peptides - adverse effects (199) 199
diabetes mellitus, type 2 - metabolism (194) 194
drug therapy, combination (192) 192
insulin secretion (191) 191
glycated hemoglobin a - metabolism (189) 189
drug administration schedule (185) 185
insulin resistance (185) 185
hyperglycemia (184) 184
health aspects (183) 183
medicine & public health (183) 183
insulin glargine (182) 182
dosage and administration (178) 178
body weight (176) 176
venoms - adverse effects (176) 176
glucagon-like peptide-1 receptor - agonists (171) 171
mellitus (170) 170
hypoglycemia (167) 167
medicine, research & experimental (162) 162
sulfonylurea (161) 161
therapy (159) 159
physiological aspects (156) 156
diabetes mellitus, type 2 - complications (154) 154
incretins - therapeutic use (151) 151
insulin - therapeutic use (148) 148
abridged index medicus (145) 145
metformin-treated patients (144) 144
glycosylated hemoglobin (139) 139
incretin (139) 139
body weight - drug effects (135) 135
pharmacokinetics (134) 134
diabetes mellitus, type 2 - physiopathology (133) 133
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2715) 2715
German (52) 52
Spanish (32) 32
French (24) 24
Korean (10) 10
Chinese (9) 9
Japanese (9) 9
Czech (5) 5
Hungarian (4) 4
Italian (4) 4
Turkish (4) 4
Polish (2) 2
Russian (2) 2
Croatian (1) 1
Danish (1) 1
Dutch (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 05/2018, Volume 20, Issue 5, pp. 1223 - 1234
Aims While pharmacological glucagon‐like peptide‐1 receptor (GLP‐1R) agonists are FDA‐approved for treating type 2 diabetes mellitus (T2DM) and obesity, a... 
antidiabetic drug | drug development | appetite control | exenatide | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | GLYCEMIC CONTROL | FOOD-INTAKE | EXENATIDE EXENDIN-4 | TREATED PATIENTS | PEPTIDE-1 RECEPTOR AGONISTS | DIABETES-MELLITUS | ENERGY-BALANCE | ENDOCRINOLOGY & METABOLISM | BODY-WEIGHT SUPPRESSION | INTRINSIC-FACTOR | Glucose Intolerance - metabolism | Nausea - chemically induced | Humans | Vitamin B 12 - analogs & derivatives | Vitamin B 12 - adverse effects | Male | Glucose Intolerance - pathology | Vitamin B 12 - therapeutic use | Glucose Intolerance - blood | Tissue Distribution | Glucagon-Like Peptide-1 Receptor - genetics | Glucose Intolerance - drug therapy | Glucagon-Like Peptide-1 Receptor - metabolism | Insulin-Secreting Cells - metabolism | HEK293 Cells | Behavior, Animal - drug effects | Female | Exenatide - pharmacokinetics | Exenatide - adverse effects | Exenatide - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Recombinant Proteins - metabolism | Exenatide - therapeutic use | Hypoglycemic Agents - pharmacokinetics | Drug Stability | Mice, Inbred C57BL | Appetite Regulation - drug effects | Recombinant Proteins - chemistry | Energy Intake - drug effects | Hypoglycemic Agents - chemistry | Blood-Brain Barrier - drug effects | Rats, Sprague-Dawley | Blood-Brain Barrier - metabolism | Nausea - prevention & control | Animals | Insulin-Secreting Cells - pathology | Vitamin B 12 - pharmacokinetics | Hypoglycemic Agents - adverse effects | Energy Metabolism - drug effects | Glucagon-Like Peptide-1 Receptor - agonists | Type 2 diabetes | Pancreatic beta cells | Diet therapy | Fluorescein | Nausea | Hypoglycemic agents | Glucose | Drug approval | Vitamins | Dextrose | Anorexia | Glucagon | Diabetes mellitus | Body weight | Central nervous system | Confocal microscopy | Hypothalamus | Vitamin B12 | Insulin | Beta cells | Glucose tolerance | Side effects | Proteolysis | Food intake | Rodents | Vagus nerve | Hypophagia | Pancreas | Diabetes mellitus (non-insulin dependent)
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2018, Volume 20, Issue 8, pp. 2034 - 2038
This study aimed to quantify the effect of the immediate release (IR) of exenatide, a short‐acting glucagon‐like peptide‐1 (GLP‐1) receptor agonist (GLP‐1RA),... 
antidiabetic drug | GLP‐1 analogue | dose–response relationship | incretin therapy | pharmacodynamics | exenatide | GLP-1 analogue | GLUCAGON-LIKE PEPTIDE-1 | ENDOCRINOLOGY & METABOLISM | dose-response relationship | Incretins - blood | Humans | Intestinal Absorption - drug effects | Glucagon-Like Peptide 1 - blood | Incretins - pharmacokinetics | Diabetes Mellitus, Type 2 - metabolism | Dietary Carbohydrates - metabolism | Systems Biology | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Hypoglycemic Agents - blood | Glucagon-Like Peptide-1 Receptor - metabolism | Hypoglycemic Agents - administration & dosage | Postprandial Period | Exenatide - pharmacokinetics | Hypoglycemic Agents - therapeutic use | Digestion - drug effects | Hyperglycemia - prevention & control | Exenatide - therapeutic use | Hypoglycemic Agents - pharmacokinetics | Blood Glucose - analysis | Drug Administration Schedule | Diabetes Mellitus, Type 2 - blood | Gastric Emptying - drug effects | Models, Biological | Drug Liberation | Exenatide - administration & dosage | Exenatide - blood | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Incretins - administration & dosage | Pharmacology | Hypoglycemic agents | Glucose | Glucagon | Dextrose | Gastric emptying | Glutamic acid receptors | Food intake
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 13, pp. 1228 - 1239
This trial, which compared once-weekly exenatide plus usual care with usual care alone in patients with type 2 diabetes with or without previous cardiovascular... 
MEDICINE, GENERAL & INTERNAL | RISK | EVENT LOWERING EXSCEL | GLUCOSE CONTROL | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Exenatide | Peptides - administration & dosage | Incidence | Cardiovascular Diseases - complications | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Venoms - administration & dosage | Female | Diabetes Mellitus, Type 2 - complications | Double-Blind Method | Drug Administration Schedule | Venoms - adverse effects | Kaplan-Meier Estimate | Diabetes Mellitus, Type 2 - blood | Least-Squares Analysis | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Usage | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Drug therapy | Observations | Myocardial infarction | Cerebral infarction | Diabetes mellitus | Pancreatitis | Amylin | Cardiovascular disease | Patients | Thyroid carcinoma | Studies | Side effects | Pancreatic carcinoma | Pancreatic cancer | Diabetes | Health risk assessment | Heart diseases | Endocrinology | Pharmaceuticals | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
LANCET, ISSN 0140-6736, 12/2014, Volume 384, Issue 9961, pp. 2228 - 2234
Background Combination treatment with a glucagon-like peptide-1 (GLP-1) agonist and basal insulin has been proposed as a treatment strategy for type 2 diabetes... 
TRIAL | METFORMIN | MEDICINE, GENERAL & INTERNAL | PLACEBO | THERAPY | GLARGINE | LIRAGLUTIDE | EFFICACY | ONCE-DAILY LIXISENATIDE | EXENATIDE | BENEFITS
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 07/2018, Volume 20, Issue 7, pp. 1602 - 1614
Aims To compare the efficacy and safety of adding the glucagon‐like peptide‐1 receptor agonist exenatide once weekly (QW) 2 mg or placebo among patients with... 
type 2 diabetes | glucagon‐like peptide‐1 receptor agonist | insulin glargine | exenatide once weekly | glucagon-like peptide-1 receptor agonist | PEPTIDE-1 RECEPTOR AGONIST | FIXED-RATIO COMBINATION | GLYCEMIC CONTROL | METAANALYSIS | ONCE-DAILY LIXISENATIDE | CONTROLLED-TRIALS | THERAPY | BASAL INSULIN | BOLUS INSULIN | ENDOCRINOLOGY & METABOLISM | PLUS | Glycated Hemoglobin A - analysis | Follow-Up Studies | Obesity - drug therapy | Humans | Middle Aged | Male | Diabetes Mellitus, Type 2 - metabolism | Weight Loss - drug effects | Hypoglycemia - prevention & control | Drug Therapy, Combination - adverse effects | Glucagon-Like Peptide-1 Receptor - metabolism | Female | Hypoglycemia - chemically induced | Diabetes Mellitus, Type 2 - complications | Exenatide - adverse effects | Body Mass Index | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Exenatide - therapeutic use | Double-Blind Method | Drug Administration Schedule | Obesity - complications | Insulin Glargine - therapeutic use | Diabetes Mellitus, Type 2 - blood | Incretins - adverse effects | Exenatide - administration & dosage | Aged | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Monitoring | Glucagon-Like Peptide-1 Receptor - agonists | Incretins - administration & dosage | Type 2 diabetes | Hyperglycemia | Glucagon | Body weight | Glycosylated hemoglobin | Glucose | Insulin | Dextrose | Diabetes mellitus | Hemoglobin | Titration | Diabetes | Metformin | Hypoglycemia | Diabetes mellitus (non-insulin dependent) | Original
Journal Article
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 08/2018, Volume 547, Issue 1-2, pp. 265 - 273
Journal Article
Japanese Pharmacology and Therapeutics, ISSN 0386-3603, 2015, Volume 43, Issue 12, pp. 1647 - 1653
Journal Article